News

Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ...

Altimmune Inc (ALT) reports a robust cash reserve and significant progress in drug trials, despite ongoing financial losses ...

ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors To Secure Counsel Before Important Deadline In Securities Class Action

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...
TipRanks on MSN8h

Altimmune Reports Promising Trial Results and Financial Growth

Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

Berger Montague PC Investigating Claims on Behalf of Altimmune, Inc. (NASDAQ: ALT) Investors After Class Action Filing

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise ...

Altimmune stock rises on promising Q2 report

Altimmune (NASDAQ:ALT) shares surge 8% post-promising Q2 results, driven by pemvidutide's success in metabolic and liver conditions. Read more here.

Altimmune Q2 FY2025 Earnings Call Transcript

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...